Table I.
Presentation, management and outcomes of patients with acute abdomen during April-July, 2020 vs. April-July, 2019.
| April-July 2020 | April-July 2019 | Fisher test (P<0.05) | |
|---|---|---|---|
| Total number | 50 | 43 | 0.9561 |
| Sex ratio (F:M) | 1:2.33 | 1:1.38 | 0.2753 |
| Age (mean ± SD) | 60.9±2.34 | 61.2±2.76 | >0.999 |
| Pathology | |||
| Occlusions: | 30 (60%) | 19 (44.2%) | 0.1486 |
| Strangulated hernia/eventration | 9 | 11 | 0.4513 |
| Adherences | 5 | 4 | >0.999 |
| Volvulus | 3 | 2 | >0.999 |
| Tumor stenosis | 10 | 1 | 0.0095a |
| Simple mechanical occlusion | 3 | 1 | 0.6211 |
| Peritonitis: | 16 (32%) | 18 (41.9%) | 0.3899 |
| Gastric perforation | 2 | 3 | 0.9862 |
| Caecal tumor perforation | 5 | 2 | 0.4447 |
| Appendicitis | 8 | 8 | >0.999 |
| Biliary peritonitis | 1 | 0 | >0.999 |
| Perforated diverticulitis | 0 | 3 | 0.0951 |
| Crohn's disease | 0 | 1 | >0.999 |
| Mesenteric ischemia | 1 | 2 | >0.999 |
| Hemorrhages | 3 | 1 | 0.6211 |
| Upper digestive bleeding | 2 | 1 | >0.999 |
| Traumatic mesenteric rupture | 1 | 0 | >0.999 |
| Neoplastic patients | 16 (32%) | 4 (9.3%) | 0.0101a |
| Management: | |||
| Surgery | 40 (80%) | 38 (88.4%) | >0.999 |
| Laparoscopy vs. open surgery | 2/38 | 9/29 | 0.0234a |
| Conservative | 10 (20%) | 5 (11.6%) | 0.3976 |
| Surgery: | |||
| Immediate | 38 | 35 | 0.9862 |
| >24 h | 2 | 3 | |
| COVID-19 status (RT-PCR) | N/A | ||
| Positive | 1 | ||
| Negative | 49 | ||
| Hospital stay (days) | 8.73±0.67 | 10.27±1.21 | |
| Postoperative complications | |||
| Deceased | 6 (12%) | 4 (9.3%) | 0.7476 |
| Nosocomial infections: | 1 (2%) | 6 (13.95%) | 0.0461a |
| Surgical wound infection | 1 | 4 | |
| Clostridium infection | 0 | 2 |
aStatistically significant difference.